Sarepta Therapeutics

biopharmaceutical company

SRPT Nasdaq ISIN US8036071004 SEC CIK 873303 LEI 549300IKDPIED8J8IG21
Follow Sarepta Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $323.8M −12.5% vs same quarter last year
Net income −$28.5M +43.7% vs same quarter last year
EPS, diluted −$0.27 +46% vs same quarter last year
Operating cash flow $60M +511.1% vs same quarter last year
Revenue by quarter
$658.4M
$611.5M
$513.1M
$370M
$442.9M
$330.5M
$328.7M
$323.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B$0$1B$2BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.9B−$713.4M
FY24$1.8B$235.2M
FY23$1.1B−$536M
FY22$843.8M−$703.5M
FY21$612.4M−$418.8M
FY20$455.9M−$554.1M
FY19$380.8M−$715.1M
FY18$301M−$361.9M
FY17$154.6M−$50.7M
FY16$5.4M−$267.3M
FY15$1.3M−$220M
FY14$9.8M−$135.8M
FY13-−$112M
FY12-−$121.3M
FY11-−$2.3M
MarginsShare of revenue
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%5000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−37.5%−38.3%
FY2412.2%13.2%
FY23−23.4%−46.8%
FY22−63.5%−83.4%
FY21−75.1%−68.4%
FY20−123.8%−121.6%
FY19−185.3%−187.8%
FY18−114.1%−120.2%
FY17−111%−32.8%
FY16−4920.3%−4930.2%
FY15−17572.5%−17560.3%
FY14−1371.2%−1391.7%
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$307.5M
FY24−$342.7M
FY23−$577.1M
FY22−$356.2M
FY21−$481.7M
FY20$25.3M
FY19−$516.1M
FY18−$449.8M
FY17−$244M
FY16−$251.2M
FY15−$152.9M
FY14−$154M
FY13−$67.1M
FY12−$29.8M
FY11−$24.9M
Returned to shareholdersDividends paid and shares bought back
$0$10M$20M$30MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$25M
FY24$0
FY23$0
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Sarepta Therapeutics
  • Healthcare median
−20000%−15000%−10000%−5000%0%5000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearSarepta TherapeuticsHealthcare median
FY25−38.3%−30.6%
FY2413.2%−47%
FY23−46.8%−58%
FY22−83.4%−80.4%
FY21−68.4%−71.8%
FY20−121.6%−62.2%
FY19−187.8%−46.2%
FY18−120.2%−49.6%
FY17−32.8%−45.9%
FY16−4930.2%−36%
FY15−17560.3%−37.8%
FY14−1391.7%−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%